Heat Biologics Remains on Track to Achieve  Multiple Topline Data Readouts this Quarter Oct 13, 2016
Heat Biologics Selects Adaptive Biotechnologies to Discover Potential Clinical Biomarkers to Advance Novel Immunotherapies Oct 11, 2016
Heat Biologics Substantially Reduces Debt and Reports Proceeds of Approximately $2.8 Million Year-to-Date from the Exercise of Warrants Oct 7, 2016
Heat Biologics Resumes Enrollment in its Non-Small Cell Lung Cancer Trial Evaluating HS-110 in Combination with Anti-PD-1 Checkpoint Inhibitor Sep 14, 2016
Heat Biologics Provides Corporate Update and Reports Second Quarter 2016 Financial Results Aug 15, 2016
